Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Asciminib Combinations for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
New Berlin, Wisconsin
This trial tests the effectiveness and safety of a medication called asciminib in patients newly diagnosed with Chronic Myeloid Leukemia in the Chronic Phase. Patients will take asciminib daily, and if they do not respond after a few years, they may also take another low-dose medication. Asciminib works by blocking a protein that helps cancer cells grow.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service